Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Vir Biotechnology Stock Soared Today

TheMotleyFool

0 0

Why Vir Biotechnology Stock Soared TodayPhoto, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Shares of Vir Biotechnology (NASDAQ: VIR) surged 32% on Tuesday after the immunology company announced promising clinical trial results for its COVID-19 antibody treatment.

Vir and its partner GlaxoSmithKline (NYSE: GSK) said an independent data monitoring committee recommended that they stop their phase 3 study of VIR-7831 early, as the experimental therapy demonstrated "profound efficacy."

Investors bid up Vir Biotechnology's stock price on Thursday. Image source: Getty Images.

Source Fool.com

Like: 0

VIR

Teilen